MPYS/STING-Mediated TNF-α, not type i IFN, is essential for the mucosal adjuvant activity of (3′-5′)-cyclic-di-guanosine- monophosphate in vivo

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 492-502

  Blaauboer, Steven M ^a   Gabrielle, Vincent D ^a   Jin, Lei ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3' 5')CYCLIC DI GUANOSINE MONOPHOSPHATE; ALPHA INTERFERON RECEPTOR; IMMUNOLOGICAL ADJUVANT; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISSOCIATION; FEMALE; GENE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STING GENE; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 84891074076     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301812     Document Type: Article

References (45)

1. Karaolis, D. K., T. K. Means, D. Yang, M. Takahashi, T. Yoshimura, E. Muraille, D. Philpott, J. T. Schroeder, M. Hyodo, Y. Hayakawa, et al. 2007. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol. 178: 2171-2181.
2. Ebensen, T., K. Schulze, P. Riese, C. Link, M. Morr, and C. A. Guzmán. 2007. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 25: 1464-1469.
3. Madhun, A. S., L. R. Haaheim, J. K. Nøstbakken, T. Ebensen, J. Chichester, V. Yusibov, C. A. Guzman, and R. J. Cox. 2011. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 29: 4973-4982.
4. Zhao, L., R. KuoLee, G. Harris, K. Tram, H. Yan, and W. Chen. 2011. c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment. Int. Immunopharmacol. 11: 1378-1383.
5. Hu, D. L., K. Narita, M. Hyodo, Y. Hayakawa, A. Nakane, and D. K. Karaolis. 2009. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 27: 4867-4873.
6. Karaolis, D. K., M. W. Newstead, X. Zeng, M. Hyodo, Y. Hayakawa, U. Bhan, H. Liang, and T. J. Standiford. 2007. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect. Immun. 75: 4942-4950.
7. Ogunniyi, A. D., J. C. Paton, A. C. Kirby, J. A. McCullers, J. Cook, M. Hyodo, Y. Hayakawa, and D. K. Karaolis. 2008. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine 26: 4676-4685.
8. Yan, H., R. KuoLee, K. Tram, H. Qiu, J. Zhang, G. B. Patel, and W. Chen. 2009. 39,59-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem. Biophys. Res. Commun. 387: 581-584.
9. Ebensen, T., R. Libanova, K. Schulze, T. Yevsa, M. Morr, and C. A. Guzmán. 2011. Bis-(39,59)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29: 5210-5220.
10. Gray, P. M., G. Forrest, T. Wisniewski, G. Porter, D. C. Freed, J. A. DeMartino, D. M. Zaller, Z. Guo, J. Leone, T. M. Fu, and K. A. Vora. 2012. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell. Immunol. 278: 113-119.
11. McWhirter, S. M., R. Barbalat, K. M. Monroe, M. F. Fontana, M. Hyodo, N. T. Joncker, K. J. Ishii, S. Akira, M. Colonna, Z. J. Chen, et al. 2009. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J. Exp. Med. 206: 1899-1911.
12. Ishikawa, H., and G. N. Barber. 2008. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455: 674-678.
13. Jin, L., P. M. Waterman, K. R. Jonscher, C. M. Short, N. A. Reisdorph, and J. C. Cambier. 2008. MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol. Cell. Biol. 28: 5014-5026.
14. Zhang, X., H. Shi, J. Wu, X. Zhang, L. Sun, C. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51: 226-235.
15. Jin, L., K. K. Hill, H. Filak, J. Mogan, H. Knowles, B. Zhang, A. L. Perraud, J. C. Cambier, and L. L. Lenz. 2011. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J. Immunol. 187: 2595-2601.
16. Sauer, J. D., K. Sotelo-Troha, J. von Moltke, K. M. Monroe, C. S. Rae, S. W. Brubaker, M. Hyodo, Y. Hayakawa, J. J. Woodward, D. A. Portnoy, and R. E. Vance. 2011. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79: 688-694.
17. Ouyang, S., X. Song, Y. Wang, H. Ru, N. Shaw, Y. Jiang, F. Niu, Y. Zhu, W. Qiu, K. Parvatiyar, et al. 2012. Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. Immunity 36: 1073-1086.
18. Yin, Q., Y. Tian, V. Kabaleeswaran, X. Jiang, D. Tu, M. J. Eck, Z. J. Chen, and H. Wu. 2012. Cyclic di-GMP sensing via the innate immune signaling protein STING. Mol. Cell 46: 735-745.
19. Ishii, K. J., T. Kawagoe, S. Koyama, K. Matsui, H. Kumar, T. Kawai, S. Uematsu, O. Takeuchi, F. Takeshita, C. Coban, and S. Akira. 2008. TANKbinding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451: 725-729.
20. Jin, L., A. Getahun, H. M. Knowles, J. Mogan, L. J. Akerlund, T. A. Packard, A. L. Perraud, and J. C. Cambier. 2013. STING/MPYS mediates host defense against Listeria monocytogenes infection by regulating Ly6C(hi) monocyte migration. J. Immunol. 190: 2835-2843.
21. Ishikawa, H., Z. Ma, and G. N. Barber. 2009. STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 461: 788-792.
22. McKee, A. S., M. A. Burchill, M. W. Munks, L. Jin, J. W. Kappler, R. S. Friedman, J. Jacobelli, and P. Marrack. 2013. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc. Natl. Acad. Sci. USA 110: E1122-E1131.
23. Burdette, D. L., and R. E. Vance. 2013. STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 14: 19-26.
24. Kayamuro, H., Y. Abe, Y. Yoshioka, K. Katayama, T. Nomura, T. Yoshida, K. Yamashita, T. Yoshikawa, Y. Kawai, T. Mayumi, et al. 2009. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 30: 5869-5876.
25. Corrigan, R. M., and A. Gründling. 2013. Cyclic di-AMP: another second messenger enters the fray. Nat. Rev. Microbiol. 11: 513-524.
26. Yao, J., N. Mackman, T. S. Edgington, and S. T. Fan. 1997. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J. Biol. Chem. 272: 17795-17801.
27. Xu, Z., R. Dziarski, Q. Wang, K. Swartz, K. M. Sakamoto, and D. Gupta. 2001. Bacterial peptidoglycan-induced tnf-alpha transcription is mediated through the transcription factors Egr-1, Elk-1, and NF-kappaB. J. Immunol. 167: 6975-6982.
28. Zhang, Z., B. Yuan, M. Bao, N. Lu, T. Kim, and Y. J. Liu. 2011. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 12: 959-965.
29. Clark, K., L. Plater, M. Peggie, and P. Cohen. 2009. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J. Biol. Chem. 284: 14136-14146.
30. Palombella, V. J., O. J. Rando, A. L. Goldberg, and T. Maniatis. 1994. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785.
31. Danilchanka, O., and J. J. Mekalanos. 2013. Cyclic dinucleotides and the innate immune response. Cell 154: 962-970.
32. Libanova, R., P. D. Becker, and C. A. Guzmán. 2012. Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb. Biotechnol. 5: 168-176.
33. Sun, L., J. Wu, F. Du, X. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786-791.
34. Wu, J., L. Sun, X. Chen, F. Du, H. Shi, C. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339: 826-830.
35. Kayamuro, H., Y. Yoshioka, Y. Abe, K. Katayama, T. Yoshida, K. Yamashita, T. Yoshikawa, T. Hiroi, N. Itoh, Y. Kawai, et al. 2009. TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem. Biophys. Res. Commun. 384: 296-300.
36. St John, A. L., C. Y. Chan, H. F. Staats, K. W. Leong, and S. N. Abraham. 2012. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat. Mater. 11: 250-257.
37. Togbe, D., S. I. Grivennikov, N. Noulin, I. Couillin, I. Maillet, M. Jacobs, M. Maret, L. Fick, S. A. Nedospasov, V. F. Quesniaux, et al. 2007. T cell-derived TNF down-regulates acute airway response to endotoxin. Eur. J. Immunol. 37: 768-779.
38. Grivennikov, S. I., A. V. Tumanov, D. J. Liepinsh, A. A. Kruglov, B. I. Marakusha, A. N. Shakhov, T. Murakami, L. N. Drutskaya, I. Förster, B. E. Clausen, et al. 2005. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22: 93-104.
39. Tumanov, A. V., S. I. Grivennikov, A. A. Kruglov, Y. V. Shebzukhov, E. P. Koroleva, Y. Piao, C. Y. Cui, D. V. Kuprash, and S. A. Nedospasov. 2010. Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood 116: 3456-3464.
40. Fei, M., S. Bhatia, T. B. Oriss, M. Yarlagadda, A. Khare, S. Akira, S. Saijo, Y. Iwakura, B. A. Fallert Junecko, T. A. Reinhart, et al. 2011. TNF-alpha from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. Proc. Natl. Acad. Sci. USA 108: 5360-5365.
41. Tartaglia, L. A., and D. V. Goeddel. 1992. Two TNF receptors. Immunol. Today 13: 151-153.
42. Faustman, D., and M. Davis. 2010. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9: 482-493.
43. Grell, M., E. Douni, H. Wajant, M. Löhden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802.
44. Jin, L., L. G. Xu, I. V. Yang, E. J. Davidson, D. A. Schwartz, M. M. Wurfel, and J. C. Cambier. 2011. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun. 12: 263-269.
45. Li, X. D., J. Wu, D. Gao, H. Wang, L. Sun, and Z. J. Chen. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341: 1390-1394.